ライフサイエンスコーパス: serotype

1 so identified epitopes unique to each Dengue serotype.

2 d loops that differ in sequence depending on serotype.

3 age, sex, disease severity, and enterovirus serotype.

4 pecific antibody responses against each DENV serotype.

5 ere a pneumococcal conjugate vaccine (PCV13) serotype.

6 ed with the prevalence of resistance in that serotype.

7 (0.25-0.69) for that caused by 3, 6A and 19A serotypes.

8 ions in pneumococcal disease caused by these serotypes.

9 sal swabs, and (iii) the distribution of GBS serotypes.

10 ; 6 of the 21 MAbs neutralized three or more serotypes.

11 nd postbooster (D301) doses for pneumococcal serotypes.

12 vity from mouse sera immunized with parental serotypes.

13 highly penetrant viruses with cross-reactive serotypes.

14 the nucleolus do not colocalize for all the serotypes.

15 o process P1 polyproteins from multiple FMDV serotypes.

16 pneumococcal disease (IPD) caused by vaccine serotypes.

17 provide long-term immunity against all four serotypes.

18 a dangerous strain among 225 E. coli unique serotypes.

19 lly enhance infection by heterologous Dengue serotypes.

20 ver, mAb 2E8 recognizes NS1 of all four DENV serotypes.

21 ional antibody responses against all vaccine serotypes.

22 with representatives from the 4 major viral serotypes.

23 ined maternal and perinatal outcomes and GBS serotypes.

24 e in this region has been determined for all serotypes.

25 OPV) for outbreak response considering all 3 serotypes.

26 y was achieved on days 7, 28, and 56 for all serotypes.

27 children younger than 5 years caused by any serotype, 0.16 (0.07-0.40) for disease caused by PCV7 se

28 0.16 (0.07-0.40) for disease caused by PCV7 serotypes, 0.17 (0.07-0.42) for disease caused by 1, 5,

29 We further show that recombinant AAV serotype 1 (rAAV1) transduces ECs of pathologic vessels,

30 eutralizing antibodies that target sigma1 of serotype 1 (T1) and serotype 3 (T3) reoviruses.

31 evolving murine antigenic epitopes on an AAV serotype 1 capsid template can evade NAbs without compro

32 tudy provides evidence that, within the same serotype 1 clonal complex, biological properties differ

33 tes) and Pakistan (Balochistan Province) and serotype 1 wild poliovirus in Pakistan, Afghanistan, and

34 (E1) specific for a potent, fully human DENV serotype 1-specific antibody, termed HM14c10, derived fr

35 ody HM14c10, which potently neutralizes DENV serotype 1.

36 ster than those given the 2 + 1 schedule for serotypes 1 (8.92 mug/mL vs 3.07 mug/mL), 4 (3.43 mug/mL

37 rocesses are surprisingly distinct among AAV serotypes 1 to 12.

38 elope (E) protein of viruses of dengue virus serotypes 1, 2, and 3 targeted by human neutralizing ant

39 We demonstrated that AAV vectors of serotypes 1, 7, 8, and 9 trafficked from the whiskerpad

40 sessed at birth, day (D) 43, and D91 for GBS serotypes; 1 month postdose 3 (D127) for diphtheria; and

41 ents with COPD and challenged with opsonized serotype 14 Streptococcus pneumoniae.

42 Using geolocated genotype (800 cases) and serotype (17,291 cases) data, we show that in Bangkok, T

43 In 2003, serotype 19A CC320 isolates containing both mef(E)/mel a

44 eclined in PCV10 and PCV13 counties, whereas serotype 19A increased in PCV10 counties.

45 Post-PCV13 declines in serotype 19A IPD in persons aged <2 years (IRR, 0.23; CI

46 Previous studies on AAV serotype 2 (AAV2) showed that assembly takes place in th

47 Using a dengue virus serotype 2 (DENV-2) vaccine strain (PDK53), we show that

48 deletion variant of the dengue virus (DENV) serotype 2 (DENV2) Tonga/74 strain lacking 30 nucleotide

49 by which several strains of human astrovirus serotype 2 (HAstV-2) are resistant to the potent HAstV-2

50 Using the Streptococcus pneumoniae serotype 2 CPS, which is synthesized by the widespread W

51 Recent detections of circulating serotype 2 vaccine-derived poliovirus in northern Nigeri

52 OPV2 cessation show continued circulation of serotype 2 vaccine-derived polioviruses (VDPVs).

53 Zika virus and dengue virus serotype 2 were isolated from a patient with travel to H

54 que variants of 3 pneumococcal strains, D39 (serotype 2), WCH43 (serotype 4) and WCH16 (serotype 6A)

55 f a recombinant adenoassociated viral vector serotype 2/5 (rAAV2/5) encoding human alpha-N-acetylgluc

56 es that target sigma1 of serotype 1 (T1) and serotype 3 (T3) reoviruses.

57 There was no effect against serotype 3.

58 Serotypes 3 (n = 38 [36.2%]) and 19A (n = 30 [28.6%]) we

59 Pneumococcal serotype 33A has two membrane-bound O-acetyltransferase

60 e 33F survived short-term drying better than serotype 33A.

61 ars not to affect cell wall shielding, since serotypes 33A and 33F exhibit comparable nonspecific ops

62 and adhesion to nasopharyngeal cells, though serotype 33F survived short-term drying better than sero

63 Serotypes 33X1 and 33X2 express novel capsule types base

64 Loss of WciG-mediated O-acetylation in serotypes 33X1 and 33X2, however, resulted in a phenotyp

65 The increased prevalence of MDR serotype 35B after the introduction of PCV13 was directl

66 We studied putative serotype 35B clinical isolates to assess the uniformity

67 The increasing incidence of serotype 35B disease and emergence of a multidrug-resist

68 Streptococcus pneumoniae serotype 35B is a nonvaccine serotype associated with hi

69 Serotype 35B is thus a likely future vaccine candidate,

70 candidate, but due to their previous rarity, serotype 35B strains have not been scrutinized for under

71 Certain previously rare serotypes, such as serotype 35B, are increasing in prevalence.

72 longing to ST156 (e.g., 9V, 14, and 19A) and serotype 35B.

73 O-acetylation but was otherwise identical to serotype 35B.

74 vely deep-branching lineages associated with serotypes 35B, 15A, and 15BC.

75 e O-acetyltransferase WciG was functional in serotype 35C but nonfunctional in serotype 42 due to a d

76 presence of O-acetyltransferase genes in the serotype 35C cps locus suggested that it could be incomp

77 In addition, the genetic distinction of serotype 35C from the closely related serotype 42 was un

78 The structure of the serotype 35C polysaccharide was recently reported, but t

79 nal in serotype 42 due to a deletion in wciG Serotype 35C was O-acetylated at the 5- and 6-positions

80 hemical structural, and serological bases of serotypes 35C and 42.

81 le genetic basis, we named its novel capsule serotype 35D.

82 3-specific 5J7 mAb epitope into dengue virus serotype 4 (DENV4).

83 ents, we assess the dynamics of dengue virus serotype 4 during the 2012 outbreak in Rio de Janeiro.

84 eutralizing antibodies and the mechanisms of serotype 4 neutralization are poorly understood.

85 eumococcal strains, D39 (serotype 2), WCH43 (serotype 4) and WCH16 (serotype 6A) in vitro.

86 uman antibodies that neutralize dengue virus serotype 4.

87 ctional in serotype 35C but nonfunctional in serotype 42 due to a deletion in wciG Serotype 35C was O

88 However, serotype 42 has only O-acetylation at 3-beta-galactofura

89 ion of serotype 35C from the closely related serotype 42 was unclear, as their reported cps loci are

90 of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain-deleted hum

91 Adenovirus serotype 5 (Ad5) is one of the most widely used viral ve

92 Human adenoviral serotype 5 (HAdV-5) vectors have predominantly hepatic t

93 engineered RD and SC versions of adenovirus serotype 6 (Ad6) to express the hemagglutinin (HA) gene

94 Serotype 6A declined in PCV10 and PCV13 counties, wherea

95 (serotype 2), WCH43 (serotype 4) and WCH16 (serotype 6A) in vitro.

96 The 2 + 1 schedule was superior for serotypes 6A, 6B, 18C and 23F (adjusted p value range <0

97 ve pneumococcal disease (MR-IPD) due to PCV7 serotypes (6B, 9V, 14, 19F, and 23F).

98 Serotype 6C increased in PCV10 counties, but not in PCV1

99 idic linkage to PG was also demonstrated for serotypes 8 and 31, whose reducing end sugars are glucos

100 Overall, 132 isolates from fatal cases were serotyped (88%) and 35 distinct serotypes were identifie

101 specific tetracysteine sequence into the AAV serotype 9 (AAV9) capsid, to permit labelling of viral p

102 MIS, using either an adeno-associated virus serotype 9 (AAV9) gene therapy vector or recombinant pro

103 e dose of intravenous adeno-associated virus serotype 9 carrying SMN complementary DNA encoding the m

104 ac gene editing using adeno-associated virus serotype 9 to deliver a single short guide RNA is target

105 In vivo, AAV9 (adeno-associated virus serotype 9)-mediated cardiac overexpression of Qki5 prev

106 Using intrathecal adeno-associated virus serotype 9-based delivery, the glutamate-gated chloride

107 nd that prior in vivo Adeno-associated virus serotype 9-mediated gene delivery of GJA1-20k to the hea

108 AND Using an in vivo Adeno-associated virus serotype 9-mediated gene transfer system, we confirmed i

109 omplementary adeno-associated viral vectors, serotype-9 (scAAV-9) in spinal cord tissues after intras

110 icrobial-resistant sequence type 156 (ST156) serotype 9V S. pneumoniae in 3 respiratory patients that

111 Botulinum neurotoxin serotype A (BoNT/A) causes a debilitating and potentiall

112 BoNT serotype A (BoNT/A) has the most prolonged or persistent

113 Recently, the BoNT serotype A (BoNT/A) subtypes A1 and A2 were reported to

114 e GD1a can associate to botulinum neurotoxin serotype A when expressed as individual trisaccharides.

115 inactivated FMDV serotypes (O, A, and Asia1 serotypes) a B cell response to FMDV SAT1 and serotype C

116 ploid isolates of C. neoformans var. grubii (serotype AA) and of hybrids with C. neoformans var. neof

117 hrough the investigation of 12 different AAV serotypes (AAV1 to -12), we find that AAP is not an esse

118 otypes, including the evolutionarily distant serotypes AAV2 and AAV5.

119 ltiple serotypes, including the most studied serotype, AAV2.

120 mpared invasive and noninvasive pneumococcal serotypes according to previous publications.

121 hybrids with C. neoformans var. neoformans (serotype AD) such aneuploidies have resulted in loss of

122 terval: 79-97%) and 80% (46-93%) for PCV7/13 serotypes among Bedouin and Jewish children <12 months o

123 to calculate incidence rate ratios (IRRs) by serotype and age using a Poisson model.

124 s (such as the associations between capsular serotype and lineage) remain in continuous flux.

125 of invasive pneumococcal disease changes by serotype and serogroup.

126 shown the compatibility of capsids from AAV serotypes and homology of recognition sites of AAV Nab l

127 ine association between carried pneumococcal serotypes and respiratory viruses during childhood commu

128 n pneumonia-associated invasive pneumococcal serotypes and RSV detection during CAAP.

129 irus (AAV) therapeutic products of different serotypes and transgenes.

130 ncluding colonization of mothers by invasive serotypes and vertical transmission to babies.

131 2016, 13 468 (94.9%) were characterized with serotyping and 12 235 (86.2%) with antibiotic susceptibi

132 disease (IPD) is usually caused by a single serotype, and dual-serotype IPD is rare.

133 .07-0.42) for disease caused by 1, 5, and 7F serotypes, and 0.41 (0.25-0.69) for that caused by 3, 6A

134 ever, it is unclear whether all pneumococcal serotypes are equally prone to such interaction.

135 ared to PCV7 serotypes, the additional PCV13 serotypes are more likely to cause bacteremic LRTI and e

136 The four dengue virus (DENV) serotypes are mosquito-borne flaviviruses responsible fo

137 UTR and P1 genomic region in all three Sabin serotypes, as well as vaccine-related viruses with multi

138 ccus pneumoniae serotype 35B is a nonvaccine serotype associated with high rates of penicillin nonsus

139 n MAbs (90.5%) neutralized at least one DENV serotype at concentrations of 1 mug/ml or less; 6 of the

140 ibody levels against each PCV13 pneumococcal serotype at D301.

141 on induced significant IgG responses for all serotypes: at day 30 compared with baseline, O1A titres

142 HCAECs were stimulated with purified Aa serotype b lipopolysaccharide (LPS) (Aa-LPS), heat-kille

143 r switching has occurred between MDR vaccine serotypes belonging to ST156 (e.g., 9V, 14, and 19A) and

144 Of importance, the predicted serotype-binding affinities and peptide-anchor motifs di

145 otulinum neurotoxins are known to have seven serotypes (BoNT/A-G).

146 cted from challenge with individual virulent serotypes, both in early challenge and after 5 months of

147 ociations exist between lineage and capsular serotype but these can be easily perturbed, such as by v

148 erotypes) a B cell response to FMDV SAT1 and serotype C was induced.

149 s (DENV), yet cross-reactivity with distinct serotypes can precipitate life-threatening clinical dise

150 identified the dominant serotype in multiple serotype carriage.

151 gated the transduction efficiency of 12 rAAV serotypes carrying an enhanced green fluorescent protein

152 f heptavalent PCV (PCV7) use, overall and by serotype category.

153 pe 2 wild poliovirus, 1 of 3 wild poliovirus serotypes causing paralytic polio since the beginning of

154 Using the changes in vaccine-serotype colonization data, the model-predicted changes

155 ng positive selection, the sequences of PorB serotypes commonly associated with invasive disease are

156 rs (6.1-16.6) for the grouped six additional serotypes contained in the 13-valent PCV (PCV13) but not

157 Disease due to grouped serotypes contained in the 23-valent pneumococcal polysa

158 redible interval [CrI] 7.8-10.3) for grouped serotypes contained in the seven-valent PCV (PCV7), and

159 mococcal disease caused by the additional 11 serotypes covered by PPV23 but not PCV13.

160 DENV2, and DENV3 were mainly neutralized by serotype cross-reactive antibodies.

161 erum samples to estimate the contribution of serotype-cross-reactive and type-specific antibodies to

162 Of the 92 serologically distinct serotypes currently defined, 49 serotypes were included

163 contrast, synapses fully intoxicated by BoNT serotypes D or E were refractory to synaptic rescue by a

164 High prevalence worldwide, and more serotype data, are relevant to prevention efforts.

165 veillance and disease control in addition to serotyping data.

166 Dengue, caused by four dengue virus serotypes (DENV-1 to DENV-4), is a highly prevalent mosq

167 and effective against all four dengue virus serotypes (DENV-1-4) in recipients of all ages.

168 em and is caused by four dengue virus (DENV) serotypes (DENV1-4).

169 These observations highlight the serotype-dependent heterogeneity of the capsid assembly

170 To explain these serotype-dependent protective capacities, many studies h

171 , using liver-targeted adenoassociated virus serotype DJ/8 (AAV-DJ/8) in BTBR wild-type and BTBR Lep(

172 more colony-forming units per mL of vaccine-serotype E coli was noted in the vaccine compared with t

173 However, other macrolide-resistant serotypes (eg, 15A and 35B) not currently represented in

174 ine containing the O-antigens of four E coli serotypes (ExPEC4V).

175 potentially acquire advantages from parental serotypes for enhancement of AAV transduction and evasio

176 To date, at least 27 different serotypes have been recognized.

177 as a critical entry receptor, different AAV serotypes have evolved distinctive interactions with the

178 sponse, however, the relative prevalences of serotypes have shifted.

179 h are constructed against the most prevalent serotypes, have caused great reductions in pneumococcal

180 a small-scale immunoisolation of the antigen serotypes HLA-A*02:01 and HLA-B*27:05 expressed on the E

181 5.0 mug of each of 3 CRM197-glycoconjugates (serotypes Ia, Ib, and III), or placebo.

182 1.5%) dominated, with 97% of cases caused by serotypes Ia, Ib, II, III, and V.

183 ity assessment (EQA) scheme for pneumococcal serotype identification has been performed over a period

184 Serotype III (61.5%) dominated, with 97% of cases caused

185 We found that covR-deficient serotype III S. agalactiae 874391 was significantly atte

186 Serotype III, associated with invasive disease, accounts

187 UAD identified the dominant serotype in multiple serotype carriage.

188 types were common among isolates of the same serotype in South Africa.

189 e incidence of UTIs caused by E coli vaccine serotypes in each group.

190 reased by 30% compared with 76% for non-PCV7 serotypes in equivalent period of vaccine use.

191 Nasopharyngeal carriage of PCV7 serotypes in Group 1 was significantly higher than in Gr

192 omparable due to an expansion of non-vaccine serotypes in Groups 2 and 3.

193 N: Our findings show that for nine of the 13 serotypes in PCV13, post-booster responses in infants pr

194 ical presentation varied with age but not by serotypes in the different conjugate vaccines.

195 urinary antigen detection (UAD) assay for 13 serotypes included in the pneumococcal conjugate vaccine

196 Furthermore, other AAV serotypes, including AAV1 and -8, require a combination

197 duction of vectors derived from multiple AAV serotypes, including the evolutionarily distant serotype

198 r (AAVR) is a key host receptor for multiple serotypes, including the most studied serotype, AAV2.

199 IPD due to non-PCV13 serotypes increased by 30% compared with 76% for non-PCV

200 ive pneumococcal disease caused by non-PCV13 serotypes increased, which suggests serotype replacement

201 gue virus NS5 also binds SLAs from different serotypes, indicating that NS5 recognizes the overall sh

202 of two or more doses of PCV13 against PCV13-serotype invasive pneumococcal disease was 85% (95% CI 3

203 data, the model-predicted changes in vaccine-serotype IPD incidence rates were similar to the observe

204 sually caused by a single serotype, and dual-serotype IPD is rare.

205 Of 701 accessory genes identified among dual-serotype IPD isolates, four were common between isolate

206 To assess factors associated with dual-serotype IPD, patient information obtained through labor

207 and find that the duration of carriage of a serotype is indeed positively correlated with the preval

208 Vaccination against all serotypes is necessary to protect susceptible animals an

209 by this vaccine against the four circulating serotypes is uneven.

210 FMDV), particularly strains of the O and SAT serotypes, is notoriously unstable.

211 Serotype IV accounted for 6% of the colonizing isolates,

212 which is considered to be the main driver of serotype IV GBS expansion in North America.

213 The majority of serotype IV isolates belonged to sequence type (ST)459,

214 duration is currently only understood at the serotype level.

215 reased production of SPN and SLO in epidemic serotype M1 and M89 S. pyogenes strains is associated wi

216 RocA reduces the ability of serotype M1 GAS isolates to express capsule and to evade

217 type-specific regulator mutations focuses on serotype M3 GAS isolates, and how the identified rewirin

218 When introduced into an emm serotype-matched invasive strain, the carrier allele (th

219 fied rewiring of regulatory networks in this serotype may be contributing to a decades old epidemiolo

220 the isolates (n = 172) identified all 10 GBS serotypes, most commonly types Ia (40% [69/172 isolates]

221 data on incidence (n = 90), CFR (n = 64), or serotype (n = 45).

222 d for M3 or M18 GAS due to isolates of these serotypes naturally harboring mutant rocA alleles.

223 tx1 or stx2 or were found to be positive for serotype O:157 when analyzed using alternative molecular

224 and 99.3% specific for detection of E. coli serotype O:157.

225 ogy and virulence of Yersinia enterocolitica serotype O:3.

226 culation of three different inactivated FMDV serotypes (O, A, and Asia1 serotypes) a B cell response

227 ues, is present in EPEC strains belonging to serotype O55:H7.

228 e to Streptococcus pneumoniae, trends in the serotype of invasive pneumococci, and invasive pneumococ

229 Although some serotypes of AAV are known to have nerve tropism, whethe

230 Among the seven major serotypes of BoNT/A-G, BoNT/A poses the most serious thr

231 It is well established that all seven serotypes of BoNTs (BoNT/A-G) require complex gangliosid

232 s reduced cross-reactivity between different serotypes of dengue and also between a single-mutation a

233 infection or vaccination.IMPORTANCE The four serotypes of dengue virus are the causative agents of de

234 where conserved sequences present in all the serotypes of Dengue virus has been employed for fabricat

235 V developed neutralizing antibodies to all 4 serotypes of DENV.

236 rovided therapeutic effects against all four serotypes of DENV.

237 explaining the long-term coexistence of many serotypes of major- and minor-group RVs.

238 iable, a feature used for identification and serotyping of various GAS strains.

239 For 30 (91%) of 33 patients with dual serotypes, one or both isolates were a pneumococcal conj

240 03), when most deaths were due to nonvaccine serotypes or in neonates.

241 The introduction of a vaccine targeting 13 serotypes (PCV13) in 2010 has led to concern that this s

242 ormally sterile body fluids, reconfirmed and serotyped pneumococcal isolates, and established antimic

243 nd provides a national reference service for serotyping pneumococcal isolates in England and Wales.

244 pisodes historically associated with vaccine-serotype pneumococci may impact the susceptibility of ch

245 Hospitalization rates of PCV13 serotype pneumonia decreased from 47.2 to 15.7 per 10000

246 distinct serotypes were identified, with no serotype predominance.

247 strains belonging to the K1 and K2 capsular serotypes, predominantly in eastern Asia.

248 of incidence, case fatality risk (CFR), and serotype prevalence.

249 r settings would depend on age of IPD onset, serotype profile, and timeliness of vaccination.

250 For non-vaccine serotypes, rates of progression among Bedouin and Jewish

251 t persist 2 years postvaccination for all 13 serotypes, regardless of age and comorbidity.

252 efficacy against each of the 4 dengue virus serotypes remains to be definitively determined.

253 To prevent serotype replacement, reduce transmission, and limit the

254 on-PCV13 serotypes increased, which suggests serotype replacement.

255 ntibodies (Abs) that strongly neutralize the serotype responsible for infection.

256 accine-targeted and non-vaccine pneumococcal serotypes showed lower rates of progression to complex O

257 of neutralization activity against all four serotypes simultaneously.

258 Till date, majorly serotype specific biosensors for dengue detection have b

259 he possibility of false result as in case of serotype specific DNA sensor.

260 ycoconjugate GBS vaccine elicited higher GBS serotype-specific antibody levels in infants until 90 da

261 ruited to the study (n=40 [20%]), functional serotype-specific antibody was similar between schedules

262 he first few weeks of life, whereas maternal serotype-specific anticapsular antibody is associated wi

263 kinetics of transplacentally transferred GBS serotype-specific capsular antibodies in the infants and

264 Adjusted odd ratios (ORs) for serotype-specific carriage rates by presence of specific

265 d indirect effectiveness of PCV by analyzing serotype-specific colonization prevalence and IPD incide

266 to -12 are all localized in the nucleus with serotype-specific differential patterns of nucleolar ass

267 led understanding of the fine specificity of serotype-specific human antibodies is vital for the deve

268 The primary endpoint was serotype-specific immunoglobulin G concentrations values

269 f the 5J7 quaternary epitope is a target for serotype-specific neutralizing antibodies after DENV3 in

270 PCV13 serotype-specific opsonophagocytic activity (OPA) titers

271 We estimated rates of pneumococcal serotype-specific progression from carriage to disease b

272 Serotype-specific protection against Streptococcus pneum

273 The discussion of serotype-specific regulator mutations focuses on serotyp

274 ker region of seven residues in NS5, rich in serotype-specific residues, is important for the recover

275 A serotype-specific urinary antigen detection (UAD) assay

276 NPs of adult C57BL/6 mice with S. pneumoniae serotype (ST) 6A or 8 and then coinfected them with mous

277 The instability of some serotypes, such as SAT2, affects the quality of vaccines

278 Certain previously rare serotypes, such as serotype 35B, are increasing in preva

279 s been visualized at a conserved site in two serotypes suggesting a propensity for sulfated-sugar bin

280 ependent enhancement of Dengue-1, 2, 3 and 4 serotypes suggesting that pre-existing immunity to Zika

281 estimates appeared more balanced within each serotype, suggesting that genotype-level heterogeneity m

282 hrough de novo adaptation, with few cases of serotype switching.

283 cell response are similar for all four FMDV serotypes tested following a homologous FMDV vaccination

284 V13) was designed to include disease-causing serotypes that are important in low-income and middle-in

285 bute to the very large numbers of rhinovirus serotypes that coexist while differing in virulence.IMPO

286 PCV failure is rare and, compared to PCV7 serotypes, the additional PCV13 serotypes are more likel

287 involvement of specific clones or O-antigen serotypes, the presence of certain horizontally acquired

288 Prevnar13 that contains CPS antigens from 13 serotypes undergo modifications or degradation during is

289 fant invasive GBS disease and the associated serotypes, updating previous estimates.

290 nce of capsid assembly processes of these 12 serotypes using combinatorial approaches that involved i

291 forming units per mL), the number of vaccine serotype UTIs did not differ significantly between group

292 Serotypes VI-IX are more common in Asia.

293 In 2014, the most common serotypes were 3, 19A and 35B.

294 Only six Salmonella serotypes were detected.

295 l cases were serotyped (88%) and 35 distinct serotypes were identified, with no serotype predominance

296 The most frequently identified serotypes were III (25%), Ia (23%), and V (19%).

297 lly distinct serotypes currently defined, 49 serotypes were included in the rounds.

298 The incidence of serotypes, where the effect of the vaccines differed, wi

299 Isolates were serotyped with the Quellung reaction or PCR.

300 scuous in promoting capsid assembly of other serotypes, with the exception of AAP4, -5, -11, and -12;